



Disease	Drug	Phase 1	Phase 2	Phase 3	NDA	Note
Pulmonary Fibrosis (ILD Orphan Drug Designation) No Adverse Effects	N115 Non-Steroidal Nasal Spray	X	X	X	→	Met (8) Medical Endpoints. Clinically & Statistically Significant.
Idiopathic Pulmonary Fibrosis (ILD Orphan Drug Designation) No Adverse Effects	N115 Non-Steroidal Nasal Spray	X	X	X	→	FEV-1, Hypoxemia, Dyspnea, Coughing, Sleep Better & more
COVID-19 Treatment (No Adverse Effects)	N115 Non-Steroidal Nasal Spray	X	X	X		Increases Nasal NO to kill Viruses/Shut IL-6
Long COVID Treatment (No Adverse Effects)	N115 Non-Steroidal Nasal Spray	X	X	X		Treats Long COVID Symptoms
Influenza Treatment & Preventative (No Adverse Effects)	N115 Non-Steroidal Nasal Spray	X	X	On Hold		Increases Nasal NO to kill Viruses/Shut IL-6
Unmet Needs - Allergic Rhinitis, COPD (Diabetic, Hypertensive, Pregnant should not take Steroids)	N115 Non-Steroidal Nasal Spray w/ no adverse effects	X	X	Protocol Ready		Safe Non-Steroidal for 30 to 60 Million People in US Alone
COPD – All Ages No Adverse Effects	N115 Non-Steroidal Nasal & Oral Spray	X	X	Protocol Ready		FEV-1, Hypoxemia, Dyspnea, Coughing
Cystic Fibrosis (ILD Orphan Drug Designation) No Adverse Effects	N115 Non-Steroidal Nasal Spray	X	X	Protocol Ready		FEV-1, Hypoxemia, Dyspnea, Coughing
Race Horses - Increase SaO2	N115 Nasal Spray	Pilot Study				Stop Nasal Bleeding
Alzheimer's	N115 Nasal Spray	X	Pilot Study			
Concussions	N115 Nasal Spray	X	Pilot Study			
Cancer Pre-Treatment	N115 Nasal Spray	X	Pilot Study			
OTC Nasal Spray sold US & China	N115 Nasal Spray	(1) US and (3) Chinese Approved Nasal Sprays				3 Million Patients Treated
Note: (7) Animal Studies	N115 Nasal & Oral Spray	(23) Sets of Human Clinical Trials Completed and Phase III Clinical Trial for IPF underway				4 Peer Reviews and 1 Pending